Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

10:07 EST 1st March 2015 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 16,000+

Extremely Relevant

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, leucovorin, and irinotecan (FOLFIRI) pl...

[News] FOLFOXIRI and bevacizumab in metastatic colorectal cancer

First-line bevacizumab with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) improves survival outcomes in patients with metastatic colorectal cancer, according to a new trial.

ASCO GI: Combining newer, more intensive first-line chemo with bevacizumab improves long-term outcome in advanced colorectal cancer

Updated results from TRIBE, an Italian phase III study of patients with metastatic colorectal cancer, indicate that FOLFOXIRI chemotherapy in combination with bevacizumab is superior to the standard FOLFIRI chemotherapy with bevacizumab. Compared to...

New First-line Option for Advanced Colorectal Cancer

In patients with advanced colorectal cancer, the rate of 5-year overall survival was twice as high with FOLFOXIRI plus bevacizumab as with FOLFIRI plus bevacizumab. Medscape Medical News

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival in adults with inoperable metastatic colorectal c...

CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen

Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer

[News] UK Cancer Drugs Fund to reassess 42 agents

National Health Service (NHS) England has announced a re-evaluation of 42 drugs funded by the controversial Cancer Drugs Fund (CDF) based on cost-effectiveness. The drugs include bevacizumab for breast, ovarian, and colorectal cancer, cetuximab for c...

Cornerstone begins Phase I trial of CPI-613 to treat metastatic colorectal cancer

Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead Altered Energy Metabolism Directed (AEMD) drug candidate, CPI-613, in combination with fluorouracil (5-FU), to treat with non-resectable metastatic colorectal cancer who hav…

[Articles] Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled tr

Adjuvant FOLFOX improves disease-free survival compared with fluorouracil plus leucovorin in patients with locally advanced rectal cancer after preoperative chemoradiotherapy and total mesorectal excision, and warrants further investigation.

Erbitux Appears Superior to Avastin for Initial Colorectal Cancer Therapy

Results of the phase III “Fire” trials were recently published in the medical journal The Lancet Oncology. The results of the study suggest that patients with metastatic colorectal cancer treated with Erbitux (cetuximab) combined with standard fi...

Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-lin...


Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer

[Articles] Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Despite prematurely terminated accrual and the lack of information about post-progression treatment, both progression-free survival and overall survival were significantly improved with bevacizumab and capecitabine compared with bevacizumab alone as ...

[News] Adenoma removal and colorectal cancer mortality

Patients who have low-risk adenomas removed have a reduced risk of dying from colorectal cancer compared with the general population, according to a new study. The researchers linked Norway's National Cancer Registry with its Cause of Death Registry...

Support for fecal testing in familial colorectal cancer screening

Fecal immunochemical tests (FIT) may be as effective as colonoscopies when it comes to detecting colorectal cancer among first-degree relatives of patients with colorectal cancer, according to a new study in Gastroenterology, the official journal of ...

New clues for the early detection of colorectal cancer

Researchers at the University of Luxembourg have identified potential new ways to test for the first signs of one of the most deadly types of cancer: colorectal cancer. They have found new "biomarkers": molecules whose increased presence or absence i...

Helpful predictability in colorectal cancer

    SOURCE Feb 20, 2015 Two recent studies in Genome Biology measuring the mutational difference between the primary and metastatic colorectal cancer confirm high concordance of mutations on the genome-wide scale. Colorectal cancer progression is linear. The alternative model of progression that are cancer types follow is branched evolution, […]

Colorectal Cancer Partnering 2009-2014

Recently added to the BioPortfolio report store, Colorectal Cancer Partnering 2009-2014 is a new report from Current Partnering published on 2014-10-31. This 150+-page report is available from $995. The Colorectal Cancer Partnering 2009-2014 report provides understanding and access to the colorectal cancer partnering deals and agreements entered into by the worlds leading healthcare companies. T...

FDA Approves Bevacizumab for Recurrent Ovarian Cancer

Bevacizumab has received FDA approval for use in combination with chemotherapy in women with platinum-resistant, recurrent ovarian cancer. Medscape Medical News

TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at

Dallas, TX (PRWEB) December 26, 2014 The report “TS-1 (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorect...

Breast, colorectal cancers remain more aggressive in children

Breast and colorectal cancers rarely occur in children, but when they do, these conditions are more precarious, according to a pair of National Cancer Data Base studies. Both breast cancer and colon cancer are known as adult conditions; 95 percent of...

[Articles] Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label,

These results suggest that continued VEGF inhibition with further bevacizumab is a valid treatment option for patients with locally recurrent or metastatic HER2-negative breast cancer whose disease was stabilised or responded to first-line bevacizuma...

[Articles] Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomis

Combination therapy with oxaliplatin provided consistently improved outcomes without adversely affecting post-relapse survival in the adjuvant treatment of stage III colon cancer, irrespective of whether the fluoropyrimidine backbone was capecitabine...

Vitamin D Protects Against Colorectal Cancer

A new study by Dana-Farber Cancer Institute investigators demonstrates that vitamin D can protect some people with colorectal cancer by perking up the immune system’s vigilance against tumor cells.R

Search BioPortfolio:

News Quicklinks